Zynerba Pharmaceuticals Inc. (ZYNE) Rose To Over An 8-Month High

Zynerba Pharmaceuticals Inc. (ZYNE) announced Tuesday morning that it has initiated its exploratory Phase 2 clinical trial of ZYN002 cannabidiol gel in children with Fragile X syndrome.

Zynerba Pharmaceuticals climbed throughout the second half of Tuesday’s session and closed up by 2.36 at $17.95 on above average volume. The stock broke out of a month and a half long trading range and set an 8 1/2 month high.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

... read more at: http://www.rttnews.com/2729634/zynerba-pharmaceuticals-inc-zyne-rose-to-over-an-8-month-high.aspx